Oncology
In Vitro Inflammation Models for Preclinical Drug Discovery
Developing new cancer therapies is complex, and generating reliable preclinical data is essential for making informed decisions at every stage of development. Cellomatics provides oncology CRO services that support biotech and pharmaceutical companies throughout the drug discovery process, from target validation and assay development to lead optimisation and candidate selection.
Our scientists work closely with clients to develop and deliver tailored oncology assays that address specific research objectives. By combining phenotypic screening, high-content imaging and translational tumour models, we help teams evaluate drug candidates more effectively and generate data that supports confident decision-making.
As a specialist cancer drug discovery CRO, we understand the challenges of balancing scientific rigour with development timelines and budget constraints. Our preclinical oncology research capabilities are designed to provide the expertise, technologies and insights needed to advance promising oncology programmes while reducing risk and avoiding unnecessary delays.
What are oncology CRO services?
Oncology CRO services help biotech and pharmaceutical companies progress cancer drug discovery projects by providing specialist research expertise and laboratory support. Rather than investing in new infrastructure or expanding internal teams, organisations can access the scientific capabilities they need through an experienced external partner.
A cancer drug discovery CRO typically supports activities such as assay development, compound screening, high-content imaging and preclinical studies. This allows research teams to generate robust data, answer critical scientific questions and keep programmes moving forward without overextending internal resources.
Many companies turn to oncology research services when they need additional expertise, faster turnaround times or access to specialised technologies. The goal is not simply to outsource experiments, but to work with a partner that understands the challenges of drug discovery and can help deliver the data needed to make confident development decisions.
Supporting cancer drug discovery
Successful drug discovery depends on making the right decisions at each stage of development. As a cancer drug discovery CRO, Cellomatics supports clients throughout this process, generating the data needed to evaluate opportunities, reduce risk and prioritise the most promising candidates.
Our scientists work with clients from target identification and target validation through to hit identification, lead optimisation and mechanism-of-action studies. At each stage, we design studies that address specific scientific questions, helping teams understand target biology, assess compound activity and build confidence in development decisions.
Through our cancer drug discovery services, clients gain access to specialist oncology expertise, advanced assay platforms and translational models that support informed decision-making. By generating robust, reproducible data early in development, our preclinical oncology research capabilities help teams focus resources on candidates with the greatest potential for success.
Oncology assay capabilities
Cancer drug discovery relies on using the right assay for the question being asked. No single model can capture every feature of tumour biology, which is why Cellomatics offers a broad portfolio of oncology assays to support different stages of preclinical research.
Our oncology CRO services include assays designed to investigate key cancer-related processes such as cell proliferation, apoptosis, DNA damage, migration, invasion and metastasis. These studies help clients understand how compounds behave in relevant cellular systems, whether they are assessing target engagement, comparing lead candidates or exploring mechanism of action.
By selecting the most appropriate assay format, readout and model system, our scientists help generate data that is practical, interpretable and aligned with the needs of each programme.
Proliferation assays
Apoptosis assays
DNA damage assays
Senescence assays
Tumour progression & metastasis models
Cancer progression is rarely driven by tumour growth alone. As cancer cells adapt, they can invade surrounding tissue, enter the circulation and establish secondary tumours in distant organs. This metastatic spread is one of the main reasons cancer becomes harder to treat, making it a critical process to study during oncology drug development.
Modelling tumour spread helps researchers understand how potential therapies affect migration, invasion, survival and colonisation in more relevant systems. These studies can show whether a compound only slows cell growth or also interferes with the behaviours that enable metastasis. By building this evidence early, drug discovery teams can make better decisions about candidate selection, mechanism of action and the likelihood of meaningful anti-cancer activity.
Adhesion assays
Migration assays
Invasion assays
Advanced oncology models
Traditional 2D cell cultures remain valuable for early-stage screening, but they often fail to capture the complexity of tumour biology seen in patients. As oncology programmes progress, more advanced models are needed to better reflect the cellular interactions, structural organisation and treatment responses found in vivo.
Advanced oncology models provide a more physiologically relevant environment for evaluating drug activity, mechanism of action and therapeutic potential. These systems can incorporate tumour architecture, microenvironmental factors and cell-cell interactions that influence treatment response. By bridging the gap between conventional cell culture and animal studies, translational models help researchers generate data that is more predictive of clinical outcomes. This can improve candidate selection, reduce development risk and provide greater confidence when advancing programmes through preclinical development.
3D tumour spheroid models
PARP & DNA repair biology
Immunogenic cell death
Immuno-oncology research services
The success of modern cancer immunotherapies has highlighted the importance of understanding how tumours interact with the immune system. Effective drug development requires more than measuring tumour cell responses alone; it also depends on understanding immune activation, immune evasion and the mechanisms that influence treatment outcomes.
Cellomatics provides immuno-oncology CRO services that support the development of immunotherapies across discovery and preclinical research. Our capabilities help clients investigate tumour-immune interactions, evaluate immune-modulating compounds and generate translational data that supports candidate selection.
As an experienced immunotherapy CRO, we work with a range of advanced cellular models and assay platforms to study immune activation, checkpoint pathways and immunogenic cell death. These approaches are increasingly important for the development of checkpoint inhibitors and combination therapies designed to improve anti-tumour immune responses.
By combining oncology expertise with translational immune models, our team helps clients answer critical research questions and advance promising immuno-oncology programmes with greater confidence.
Oncology screening technologies
Oncology screening technologies help research teams look beyond simple measures of cell growth and understand how a compound is behaving in a biological system. For cancer drug discovery, this can mean assessing changes in viability, morphology, signalling, DNA damage, immune activation, migration or invasion across relevant tumour models.
Cellomatics uses a range of screening approaches to support oncology programmes, from targeted assay readouts to phenotypic screening and high-content imaging. The focus is not just on generating more data, but on producing results that help clients make clear decisions about which compounds to progress, refine or deprioritise.
By combining appropriate assay design with robust analysis, oncology screening can reveal mechanism of action, treatment response and potential liabilities earlier in development.
Flow cytometry & cell phenotyping
Tumour profiling & biomarker discovery
Phenotypic screening & high content analysis
Phenotypic screening & high content analysis
Phenotypic screening enables researchers to evaluate how compounds affect cellular behaviour without requiring a predefined target. By combining high-content imaging with quantitative analysis, these approaches can reveal changes in morphology, viability, signalling pathways and treatment response across large compound libraries. As a provider of phenotypic screening CRO services, Cellomatics helps clients identify and prioritise promising candidates based on functional biological outcomes. Our cell-based screening CRO services and screening assays CRO capabilities support both focused studies and large-scale campaigns, generating the data needed to make informed decisions and progress the strongest candidates through the drug discovery pipeline.
Cancer models & therapeutic areas
No two cancer types behave in exactly the same way. Differences in tumour biology, genetic drivers, treatment response and interactions with the tumour microenvironment mean that selecting the right model is critical for generating meaningful preclinical data.
Cellomatics supports a broad range of oncology programmes using cancer models tailored to specific scientific questions and therapeutic objectives. Our experience spans both solid tumours and haematological malignancies, with expertise across breast cancer models, lung cancer models, colorectal cancer models and immuno-oncology models. Depending on the stage of development and study objectives, we work with established cancer cell lines, primary cancer cells and patient-derived models that provide greater clinical relevance.
Different therapeutic approaches require different assay strategies and oncology disease models. A targeted therapy programme may require detailed mechanism-of-action studies, while immunotherapy projects often depend on more complex immuno-oncology models that capture tumour-immune interactions. By combining biologically relevant systems with robust experimental design, our translational oncology models help researchers better understand drug activity, treatment response and resistance mechanisms.
Whether supporting early discovery, lead optimisation or translational research, we help clients select the most appropriate models to generate data that informs decision-making and supports successful programme progression.
Why choose Cellomatics for oncology research?
As a specialist provider of oncology CRO services, Cellomatics combines scientific expertise with the flexibility needed to support fast-moving drug discovery programmes.
- Dedicated cancer drug discovery CRO with expertise across oncology assays, screening platforms and translational research.
- Flexible study design and bespoke assay development tailored to specific scientific objectives.
- Access to biologically relevant models, including primary human cells and advanced translational disease models.
- Strong experience supporting both targeted therapies and immuno-oncology programmes.
- High throughput screening capabilities for efficient compound evaluation and candidate prioritisation.
- Direct access to experienced scientists throughout every project, ensuring clear communication and rapid decision-making.
- Collaborative oncology research services designed to generate robust data that supports confident development decisions.
Our goal is simple: to provide scientifically rigorous, actionable data that helps clients move oncology programmes forward more efficiently.
FAQ's
Oncology CRO services cover a wide range of research activities that support cancer drug discovery and development. These can include oncology assays, assay development, phenotypic screening, high-content imaging, biomarker studies, tumour profiling and translational research. Many organisations also provide access to specialised models and technologies that help generate the data needed to make informed development decisions.
A cancer drug discovery CRO helps researchers progress programmes from early target validation through to candidate selection. By providing specialist expertise, established workflows and preclinical oncology research capabilities, CRO partners can accelerate timelines, reduce internal resource requirements and generate robust data that supports critical development decisions.
The choice of model depends on the scientific question being addressed. Common approaches include cancer cell lines, primary patient samples, spheroid models and other translational disease models designed to better reflect tumour biology. These oncology models help researchers evaluate drug activity, treatment response and mechanisms of resistance in more relevant experimental systems.
The choice of model depends on the scientific question being addressed. Common approaches include cancer cell lines, primary patient samples, spheroid models and other translational disease models designed to better reflect tumour biology. These oncology models help researchers evaluate drug activity, treatment response and mechanisms of resistance in more relevant experimental systems.
Oncology CRO services improve study outcomes by combining specialist expertise with appropriate model selection, assay design and data analysis. Through translational oncology research and advanced oncology screening services, researchers can generate more relevant biological insights, identify promising candidates earlier and make better-informed decisions throughout the drug discovery process.
Partnering with a cancer drug discovery CRO gives organisations access to specialised oncology research services without the need to build additional in-house capabilities. This can be particularly valuable during early-stage oncology drug discovery, where rapid access to expertise, screening platforms and translational models can help reduce risk and accelerate programme progression.
Request a consultation with Cellomatics Biosciences today
As part of our oncology CRO services, our experienced team of in vitro laboratory scientists will work with you to understand your project and provide a bespoke project plan with a professional, flexible service and a fast turnaround time.
To request a consultation where we can discuss your exact requirements, please contact Cellomatics Biosciences.
